Kornimate/medical-research-clean huggingface dataset:
mind-matosinhos: multiple interventions to prevent cognitive decline

Conditions: Cognitive Dysfunction; Cognition Disorder; Memory Disorders; Cognitive Impairment; Neurocognitive Disorders

Summary: the present study aims to quantify the impact of a multidomain approach to prevent cognitive decline in individuals from the general population at-high risk of dementia. it will be based on five distinct components: 1) cognitive training; 2) physical exercise; 3) nutrition education; 4) capacitation to deal with cognitive decline; 5) assessment and correction of hearing loss.

this is a community-based randomized controlled trial (rct), which will be implemented in matosinhos municipality (portugal) and will be conducted over three months, possibly extensible up to 12 months. eligible individuals (n=300) will be randomized (1:1) into two arms: intervention and control groups. the intervention plan will be composed by five non-pharmacological strategies, namely: 1) cognitive training; 2) physical exercise; 3) nutrition education; 4) capacitation to deal with cognitive decline; 5) assessment and correction of hearing loss. this plan will be applied to both groups, but with lower intensity among the control group. participants' characteristics will be assessed at baseline and at three months; for those who complete one year of intervention, additional follow-ups at six and 12 months after the beginning of the intervention will be conducted. these evaluations will cover the following domains: sociodemographic, lifestyle, health and anthropometric characteristics; cognitive function; subjective memory complains; symptoms of anxiety and depression; quality of life; physical performance; levels of glycated hemoglobin and 24-hour urinary sodium, potassium, creatinine excretion as well as ph. the results of the present study may guide future clinical practices and health policies aiming to prevent cognitive decline and reduce the overall burden of dementia.

Eligibility criteria:
inclusion criteria: * age 18-85 years; * score equal or higher than the validated cutoff points defined as 2 standard deviations below the mean for age and education in the montreal cognitive assessment (moca); * ≥6 points on the cardiovascular risk factors, aging and dementia dementia risk score (caide); * ≥4 years of schooling. exclusion criteria: * medical disability that contraindicates physical activity; * lack of autonomy in daily activities; * previous diagnosis of dementia or severe incapacity.

Keywords: aging cognitive dysfunction cognition disorders dementia diet, healthy exercise therapy hearing loss memory disorders multidomain intervention randomized controlled trial
noninvasive vs. invasive lung evaluation

Conditions: Non-Small Cell Lung Cancer

Summary: tumor derived cell free dna (cfdna) is increasingly used in the clinic to obtain genotype information about lung cancer, but its concordance with concurrent tumor-derived sequenced data is not known. the purpose of the trial is to determine the non-inferiority of cfdna-based vs. tumor tissue-based genotyping as it pertains to the detection of national comprehensive cancer network (nccn)-recommended biomarkers in first line, treatment naive, non-squamous non-small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * patients with nsclc, which is: (1) biopsy-proven (confirmatory biopsy must have been collected within 12 months prior to enrollment), (2) metastatic (stage iv, stage iiib when curative intent is not an option, or relapsed/recurrent disease after original diagnosis of stage i-iiia), (3) non-squamous histology (mixed squamous and adenocarcinoma is allowed), (4) no prior treatment for advanced stage nsclc: (a) resection of or radiation to a single metastatic site is allowed if there are other untreated and measurable sites of metastatic disease at the time of enrollment. (b) patients who have previously undergone surgical resection or radiation for stage i-iiia nsclc are eligible if primary treatment was completed at least 6 months prior to the development of metastatic disease; for patients who received adjuvant systemic therapy, the last dose of treatment must be given at least 6 weeks prior to enrollment. * age ≥ 18 years * ability to understand a written informed consent document, and the willingness to sign it. * willingness to provide blood sample at the time points of pre-treatment, approximately 2 weeks after initiation of systemic treatment, and end of study). * patient has or will have standard-of-care tissue genotyping ordered. if the physician intends to order tissue genotyping, but there is insufficient material for analysis, the patient is still eligible for enrollment. exclusion criteria: * pregnancy * any other concurrent malignancy except for localized, non-melanoma, cutaneous cancer or non-invasive cervical cancer. any prior cancer other than nsclc must have occurred more than 2 years prior to study entry with no evidence of currently active disease. * prior treatment for metastatic nsclc including but not limited to: (1) systemic treatment (targeted therapy, chemotherapy, immunotherapy, biologic therapy, etc.), (2) resection of a metastatic lesion if the resected metastasis had been the only site of measurable metastatic disease, or resection of more than one metastatic lesion, (3) radiation of a metastatic lesion or resection bed if given to the only measurable site of metastatic disease, or radiation to more than one metastatic lesion.
pre-operative guided meditation to reduce pre-operative anxiety in patients undergoing cancer-directed surgery

Conditions: Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm

Summary: this clinical trial tests how well guided meditation, compared to silence, works to reduce pre-operative anxiety in patients undergoing cancer-directed surgery. pre-operative anxiety affects patient experience and has been found to be a predictor of severe post-operative pain and chronic pain after surgery, influencing the success and quality of a patient's recovery. while medication is often prescribed to improve anxiety symptoms, research has showed that mindfulness techniques can be used to decrease anxiety, improve comfort, and can impact both psychological and physiologic symptoms. completing pre-operative guided meditation may work well to reduce pre-operative anxiety in patients undergoing cancer directive surgery.

primary objective: i. to improve is pre-operative patient anxiety in surgical settings. outline: patients are randomized to 1 of 2 arms. arm i: patients listen to 10 minutes of guided meditation prior to surgery. arm ii: patients wear noise cancelling headphones for 10 minutes prior to surgery. after completion of study intervention, patients are followed up for up to 6 months.

Eligibility criteria:
inclusion criteria: * participants will be recruited among patients who are scheduled for cancer-directed surgery * participants must be 18 years or older exclusion criteria: * participants will be excluded from the study if they cannot speak english (as the meditation is recorded in english) * currently incarcerated * have a diagnosis of dementia * are admitted to the intensive care unit (icu) * have a hearing impairment that would make them unable to hear the recorded meditation
parkinson disease before and after medication and rehabilitation treatment

Conditions: Parkinson Disease

Summary: in this three-year project, our research teams are going to consecutively explore these important clinical, drug and physical rehabilitation treatment effects, noradrenergic network, autonomic dysfunction and microrna signalling data as well as the correlations between them in early parkinson disease (pd) patients. the investigators hypothesize that the explorations of the above insights are unique and can provide an important source data for taiwanese parkinson disease (pd).

(1) 70 patients with pd. (2) 30 age and sex-match controls. methods: -1st year to built up the biobank of 30 early pd patients (hoehn and yahr stage 1-3) and 30 health controls in all examination. the pd patients will accept the mri, autonomic dysfunction, and peripheral microrna examination and their correlations among each other at least 12 hours after the least medication. -2nd year second year, the investigators will follow-up the 30 pd patients enrolled in the 1st years. the pd patients will receive studies to evaluate the pharmacokinetics effect before medication, including mri, autonomic dysfunction, and peripheral microrna examination. -3rd year the investigators will study the rehabilitation effect in pd (3 days per week, for 12 weeks). 30 pd with rehabilitation and 30 pd without rehabilitation will be enrolled and compared their difference in mri study, autonomic dysfunction, and peripheral microrna examination before and after 3 month follow-up. goals 1. to define the effect of norepinephrine network to autonomic dysfunction in pd 2. to define the effect of peripheral microrna level to norepinephrine network in pd 3. to associate drug/physical rehabilitation effect to alteration of norepinephrine network, autonomic dysfunction, and peripheral microrna and their interactions to striatal dopaminergic network in pd. 4. according to previous results, to verify the role of norepinephrine network and autonomic dysfunction in long-term pd evolution.

Eligibility criteria:
inclusion criteria: * in this study, the patients should be 40-75 years of age and identified as pd. pd patients with an early clinical stage (hoehn and yahr stage 1-3) will be enrolled in this study. the informed written consent which is approved by ethics committee of our hospital will be obtained from the patient or their family. exclusion criteria: * patients with the following conditions are excluded: 1. atherosclerotic narrowing on intracranial and extracranial vessels (\>50% stenosis) with or without evidence of old cerebral infarctions, coronary artery diseases status post percutaneous transluminal coronary angioplasty or bypass surgery and renal failure requiring hemodialysis or peritoneal dialysis 2. moderate to severe heart failure (nyha class iii and iv). 3. central or peripheral disorders known to affect autonomic nervous systems.

Keywords: parkinson disease autonomic nervous system microrna inflammation oxidative stress noradrenergic network rehabilitation treatment
cerebral oxygenation and neurological outcomes following critical illness

Conditions: Critical Illness; Sepsis; Delirium; Respiratory Failure

Summary: purpose of the study critical illness requiring life support affects over 150 000 people in ontario every year. with aggressive support, the number of people who die from critical illness is decreasing. however, people who survive often have neurological problems. these neurological problems often include difficulties with memory, concentration, and attention. these problems are associated with poor quality of life among survivors of critical illness. the aim of this study is to identify the factors that contribute to these neurological deficits. specifically, the investigators are testing whether changes in oxygen delivery to the brain during critical illness are related to both short- and long-term neurological complications. procedures involved in the research when patients are diagnosed with a critical illness such as shock or respiratory failure, they are treated with intravenous fluids, medications to raise their blood pressure, and can be placed on a ventilator to assist with their breathing. they are observed in an intensive care unit (icu). this research protocol does not interfere with the normal treatment of patients with critical illness. the procedure involved in this research protocol requires the placement of two stickers to either side of the patient's forehead, and information about oxygen delivery to the brain will be recorded. when the patient has recovered from the critical illness, they will be asked to perform several neurological tests. some of these tests will be done with a pencil and paper, while others will use a robotic device to test arm movements, reaction time, and concentration. potential harms, risks or discomforts: this research study involves the placement of a sticker sensor to either side of the forehead. rarely, patients may develop a rash to these electrodes. the investigators monitor patients very carefully for rashes, and if a rash is to occur, the sticker sensor will be removed. with regards to the neurological testing, rarely patients can have some mild muscle stiffness after moving their arms in the robot. the investigators do not expect any other further harms, risks, or discomforts.

a detailed protocol is currently under review for funding at physician services incorporated, and can be included pending decision.

Eligibility criteria:
inclusion criteria: * critically ill patients defined as having either: 1. respiratory failure: defined as invasive mechanical ventilation for a predicted duration of \>24 hours, or: 2. shock: defined as being on one of the following agents: * norepinephrine (\>5 mcg/min) iv * epinephrine (at any dose) * vasopressin (in combination with another pressor) * milrinone (in combination with another pressor) exclusion criteria: * expected survival \<24 hours * history of cognitive dysfunction * unable to participate in follow up testing
oral supplementation with selenium in patients with mild thyroid orbitopathy

Conditions: Thyroid Orbitopathy

Summary: background: the activity of thyroid orbitopathy can be evaluated with cas (clinical activity score) based on 7 inflammatory signs. selenium acts as an oxide-reducing agent in thioredoxin-reductase, and as an anti-inflammatory agent by reducing the hydroxy peroxide intermediates on the cyclo-oxygenase pathways. increased oxidative stress has been observed in graves' disease and therefore, by incorporating an antioxidant such as selenium in patients with mild thyroid ophthalmopathy, inflammatory activity could be reduced or inactivated. general objective: to determine the clinical differences between patients with mild thyroid orbitopathy who were administered oral supplementation with selenium and patients who were administered oral placebo.

this is a simple controlled clinical trial. in which 66 eyes of 33 patients were studied. fifteen patients were assigned to the placebo group and 18 to the selenium group. we randomized into two groups the patients with mild clinical activity according to cas score. group a took placebo pills twice a day which consisted in 100µg of starch, and group b took a pill of selenium 100 µg twice a day. all the subjects tool the pills during six months. patients of both groups where examined and evaluated with cas score before and after the first, third and sixth month of treatment.

Eligibility criteria:
inclusion criteria: * patients with active mild thyroid orbitopathy according to cas scale. * older than 18 years of age. exclusion criteria: * patients with mild thyroid orbitopathy undergoing treatment with corticosteroids. * active smokers * patients allergic to selenium * follow-up shorter than 6 months
hemi-gland cryoablation for prostate cancer at ucla

Conditions: Prostate Cancer; Prostate Adenocarcinoma; Prostate Disease

Summary: this is a prospective data collection of men who are electing to undergo prostate hemi-gland cryoablation. the purpose of this observational research study is to investigate the localized treatment of prostate cancer using hemi-gland cryoablation. ucla patients undergoing hemi-gland cryoablation are a unique cohort compared to prior research because all patients at ucla have had a pre-treatment multi-parametric mri and ultrasound fusion targeted biopsy; they will be followed in a similar fashion. this results in more precise assessment of a target region of cancer for ablation which may, in turn, result in improved clinical outcomes.


Eligibility criteria:
inclusion criteria: * patient has undergone or has elected to undergo hemi-gland cryoablation at ucla * low or intermediate risk prostate cancer (gleason ≤ 7) or select high-risk patients (gleason 8 prostate cancer). * prostate volume of ≤ 70 cc * ability to complete informed consent form exclusion criteria: * medical contraindication to follow-up multi-parametric magnetic resonance imaging (mpmri) or prostate biopsy * patients unable to tolerate general or regional anesthesia.

Keywords: prostate cancer cryoablation
a randomized double blind placebo control study of huang-chi-wu-wu- tang in patients with intracranial arterial stenosis

Conditions: Intracranial Arterial Stenosis

Summary: intracranial arterial prominent stenosis (iaps) is one of main cause of stroke especially in asia. although antiplatelet aggregative or anticoagulant agent and even surgical operation are used to treat patients with iaps, the incidence of stroke occurrence still remains high. in addition, symptomatic iaps most common cause continuous deterioration, thus, increase the incidence of stroke. therefore, there is a good method to reduce the inceidence of stroke that is to prevent the progressive deterioration of iaps. huang-chi-wu-wu-tang is made of astrgalus membranaceus (fisch.) gge , paeonia lactiflora pall , cinnamom twig , zingiber officinale rose , ziziphus jujube mill , and can treat hemiplegia in the traditional chinese medicine writings. astragaloside iv is a component of astrgalus membranaceus, may reduce th cerebral infarction area in middle cerebral arterial occlusion mice. the investigators previous studies have known that paeoniflorin that a component of paeonia lactiflora pall can decrease the cerebral infarction area and neurological deficit in middle cerebral arterial occlusion rats. therefore, the purpose of the present study was to investigate the effect of huang-chi-wu-wu-tang on patients with iaps.


Eligibility criteria:
inclusion criteria: 1. had received transcranial doppolar sonography. 2. age \>40 years old. 3. gender: male or female. 4. the subject or their legal representative gave written informed consent to participate. 5. meet with one of the two transcranial doppolar sonography results below: * the evaluated standard of mca m1 stenosis of 50-99% are as follows: * psv \>140 cm/s * mfv \>100 cm/s * the evaluated standard of ba stenosis of 50-99% are as follows: * psv \>100 cm/s * mfv \>60 cm/s exclusion criteria: 1. refused to sign the informed consent form. 2. too irritable to accept the evaluation. 3. age ≦40 years old. 4. major diseases such as myocardial infarction、heart failure、chronic pulmonary obstructive disease(copd）with dyspnea、liver failure or renal failure. 5. pregnancy or breast-feeding.

Keywords: huang-chi-wu-wu-tang intracranial arterial prominent stenosis
development of a robotic ankle assist device

Conditions: Cerebral Palsy

Summary: the overall objectives of this work is to establish feasibility of a robotic ankle assist device (raad) to improve mobility in free-living settings and to establish the raad as an effective tool to provide increased dose and precision of targeted ankle therapy. the first specific goal is to assess the benefits of repeated gait training with raad assistance. individuals with cp will participate in a 4-week assistance intervention and mobility outcomes will be quantified pre and post intervention. the second specific goal is to separately assess the benefits of repeated gait training with raad resistance. individuals with cp will participate in a 4-week resistance intervention and mobility outcomes will be quantified pre and post intervention. assessed separately, it is hypothesized that both assistance and resistance training will improve mobility outcomes.


Eligibility criteria:
inclusion criteria: diagnosis of cerebral palsy. any sex, race, ethnicity or socioeconomic status. gmfcs level i, ii, or ii. ability to walk for at least 6 minutes (assisted or unassisted). age between 8-18 years. height/weight/bmi between the 5th - 95th percentile of children with cp. able to understand and follow simple directions. able to complete 5 heel raises with minimal assistance (balance only). at least 20 degrees of passive ankle plantar flexion range of motion. exclusion criteria: knee extension or ankle dorsiflexion contractures greater than 15 degrees. health condition or diagnosis other than cp that would affect safe participation. orthopedic surgery completed in the prior 12-months. current enrollment in a conflicting research study.
immunotherapy of chronic kidney failure

Conditions: Renal Failure Chronic

Summary: kidney failure can result from inflammatory renal disease in the context of autoimmunity because the kidney is targeted by host's immune response against self. there are many causes to this, but abnormal kidney function tests, i.e., bun and creatinine, can reveal the disease. oral delivery of kidney cells is ought to produce the immune tolerance - phenomenon is known as oral tolerance. preliminary studies produced convincing evidence that this hypothesis holds true and has not produced any adverse side effects. intended open label phase ii aims to confirm these findings.


Eligibility criteria:
inclusion criteria: * baseline level of creatinine twice above normal exclusion criteria: * baseline level of creatinine normal
depakote-er for depressive and bipolar depression

Conditions: Bipolar Disorder

Summary: obtain information using a randomized treatment to assess the antidepressant and anxiolytic efficacy of divalproex vs. placebo for nonrefractory bipolar patients with major depressive episodes.

study is 6 weeks long, with 7 clinical visits.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of bipolar disorder type i or ii, non refractory, non-psychotic; females must be nonpregnant/nonlactating; sexually active females must use adequate contraception; mrs \ 17; no other baseline mood stabilizing drugs, antidepressants or antipsychotics exclusion criteria: * active substance abuse or dependence in the past month; medically unstable condition; previously intolerance to valproate; past hepatitis b or c, or serious liver disease; serious suicidality
hip mobile: a community-based monitoring, rehabilitation and learning e-system for patients following a fracture

Conditions: Hip Fractures

Summary: approximately 30,000 adults in quebec over the age of 50 suffer a fragility fracture each year. fractures can affect a person's health, well-being and autonomy. personal costs of these fractures are high, with as many as 50% of hip fracture patients being unable to return their pre-fracture level of autonomy. homecare and community services provide customary rehabilitation support immediately following discharge from acute-care, though this contribution can be limited by lack of resources. for those patients at risk of negative outcomes, we have demonstrated clinically important benefits of extended exercise rehabilitation programs offered beyond the regular rehabilitation period on improving physical function. through advances in sensor and telecommunication technology, ehealth solutions incorporated within homecare services as an integral part of the continuum of care can lead to better patient and health professional experience, improve clinical outcomes and reduce costs to the healthcare system. the purpose of this study is to determine if the implementation of a 3-month community-based extended-rehabilitation e-monitoring and coaching support program is more effective at improving mobility in community-dwelling elderly patients who have sustained a fracture than a printed material support program, and if these effects persist 6 months after discontinuation.


Eligibility criteria:
inclusion criteria: * community dwelling men and women aged ≥ 60 years * treated for any fracture excluding hands, feet, patella, cervical spine, skull, ribs, or clavicle, at any of the 3 participating sites, within the previous 8 weeks. exclusion criteria: * upper limb fractures that do not meet the criteria of gait frailty * multiple traumas * open fractures * pathological fractures * inability to communicate adequately in either french or english * inability to give written informed consent * discharge to a long-term care institution